Supernus Pharmaceuticals | SUPN - Assets


Supernus Pharmaceuticals reported $1.43B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Aurora Cannabis CAD 601.09M 174.2M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026
Xeris Pharmaceuticals USD 392.01M 8.49M Mar/2026